The present invention is related to radiation oncology and, more specifically, to accurately determining the location of a target for delivering external radiation.
Cancer begins in the cells of the patient and forms malignant tumors that are often treated by surgical resection. Such surgical treatments attempt to remove as much of a tumor as possible, but cancerous cells infiltrate into the tissue adjacent the tumor such that there is no clear boundary. Also, certain procedures seek to limit the treatment margin around the tumor to reduce the amount of healthy tissue removed from the patient. In breast cancer, for example, patients prefer to limit the size of the lumpectomy resection to avoid excessive reduction or non-uniformities of the breast. Both of these factors limit the efficacy of surgical procedures for treating cancer. As such, radiation therapy has become a significant and highly successful process for treating breast cancer, lung cancer, brain cancer and many other types of localized cancers. Radiation therapy is particularly useful for treating (a) tissue after resecting a tumor, (b) centrally located tumors, and/or (c) small cell tumors that cannot be surgically resected. Radiation therapy can also be used as a palliative treatment when a cure is not possible.
Breast cancer has recently been treated by surgically resecting cancerous breast tissue and subsequently treating the remaining tissue surrounding the resection cavity using radiation. Proxima Corporation and Xoft, Inc. have developed breast brachytherapy devices and systems for selectively irradiating the portion of the tissue surrounding the resection cavity created by a lumpectomy. The existing breast brachytherapy devices have a balloon configured to be implanted in the cavity within the breast and an internal radiation source that can be placed within the balloon. After performing a lumpectomy, the balloon is inserted into the surgical cavity and inflated until the balloon presses against the tissue. The balloon is typically left in the patient for approximately five days over which two radiation treatments per day are performed. Each radiation treatment includes inserting the radiation source into the balloon and activating the radiation source to deliver ionizing radiation for approximately 10-15 minutes. After all of the radiation treatments have been performed during the multi-day course of treatment, the balloon is deflated and removed from the patient.
Breast brachytherapy procedures, however, can be challenging. For example, it may be difficult to determine whether the balloon has been inflated accurately and to monitor the balloon to ensure that the balloon has maintained the desired size throughout the multi-day course of treatment. The size of the balloon is currently determined by instilling radiopaque contrast into the balloon and measuring a resulting CT or X-ray image using a ruler. The patient must accordingly undergo a CT scan or another type of X-ray to obtain the image, and then a practitioner must evaluate the image to determine if the balloon is at the desired size. This is time-consuming and expensive, and it should be performed each day during the course of treatment. This process also exposes the patient to additional radiation.
Breast brachytherapy may also have disadvantages associated with using an internal radiation source. For example, the balloon may move within the lumpectomy cavity over the course of treatment, which can cause the internal radiation source to over irradiate some areas and under irradiate other areas. Many existing systems do not detect the relative position between the balloon and the breast to mitigate this problem. Moreover, when the radiation source is asymmetrically positioned within the balloon (e.g., spaced apart from a rotational center line of the balloon), the rotational orientation of the balloon within the lumpectomy cavity can cause the radiation source to be located at an undesirable position relative to the tissue. Conventional techniques also do not identify the rotational orientation of the balloon. This can be problematic because the balloon can move after it has been implanted over the course of treatment, or the balloon may not inflate as planned. Conventional breast brachytherapy systems are also relatively large because they must contain both a balloon and an internal radiation source. Many patients are not comfortable with having a radiation source within their body or with having a large catheter projecting from their body for a number of days, and therefore a sizable number of patients elect not to undergo breast brachytherapy.
In light of the challenges associated with breast brachytherapy procedures, partial breast irradiation using an external radiation beam has been proposed. Although radiation beams, such as Three-Dimensional Conformal Radiation Therapy beams, can shape radiation beams to conform to the target tissue, it is still difficult to use external beam radiation to treat the tissue around the resection cavities in many applications. For example, the size and shape of the cavity may change over the multi-day period typically required for external beam radiation treatments, or the treatment target may move during the treatment sessions. As such, there is a need for improving external beam radiation for partial breast irradiation and other procedures that seek to irradiate controlled treatment margins around resection cavities.
This outlines the devices and methods for a system to enable the use of removable fiducials for radiation therapy. Specific details of several embodiments of the disclosure are described below with reference to implantable devices and methods for external beam radiation treatments. Although many of the embodiments are described below with respect to partial breast irradiation systems and procedures for treating resection cavities, the systems and implantable devices can be used in other procedures for treating other indications. Moreover, several other embodiments of the invention can have different configurations, components, or procedures than those described in this section. For instance, the apparatus and methods can have one or more markers or other components for use in external beam radiation therapy procedures as described in U.S. patent application Ser. No. 11/165,843, filed on 24 Jun. 2005, and Ser. No. 11/166,801, filed on 24 Jun. 2005, PCT Application No. PCT/US08/70682, filed on Jul. 21, 2008, all of which are incorporated herein in their entirety by reference. In other instances, well-known structures associated with target locating and tracking systems have not been shown or described in detail to avoid unnecessarily obscuring descriptions of the embodiments of the invention. A person of ordinary skill in the art, therefore, will accordingly understand that the invention may have other embodiments with additional elements, or the invention may have other embodiments without several of the features shown and described below with reference to
One embodiment of an implantable device for guided radiation therapy comprises an active marker having a circuit configured to be contained in an external sheath which is implanted in a patient and to transmit a wirelessly transmitted location signal from within the patient in response to a wirelessly transmitted source energy. In an alternative embodiment, the active marker transmits a location signal along a wire. The implantable device can further include a fastening unit for retaining the marker in a fixed position in the external sheath. The marker, for example, can comprise a leadless marker having a circuit with a core and a coil around the core.
Another embodiment of an implantable device for guided radiation therapy comprises an active marker configured to be pre-loaded into a catheter; the catheter is configured to be removeably implanted in the tissue of a patient. The marker transmits a non-ionizing wireless signal in response to a non-ionizing wirelessly transmitted source energy. The implantable device can further include a stability element coupled to the marker and an explant line. The stability element is configured to hold the marker at fixed location within the catheter (e.g., known location) with respect to a target in the tissue. The explant line has a first portion coupled to the marker and/or the stability element and a second portion configured to be at least proximate to the dermis of the patient.
Another embodiment of an implantable device for guided radiation therapy comprises an active marker configured to be positioned within a capsule configured to be implanted in a cavity of a patient, and to transmit a non-ionizing wireless signal in response to a non-ionizing wirelessly transmitted source energy. The device further includes a fastening unit coupled to the active marker and configured to (a) hold the marker at a desired location in the removable implant and (b) recognize deformation of the tissue cavity.
1. Embodiments of Localization Systems and Implantable Devices
As further shown in the above-referenced applications, the localization system 10 can determine the location of the active markers 40 in real-time to facilitate external beam radiation therapy for partial breast irradiation or other therapies. The localization system 10 can include a controller 80 and a field device 60, 70 (e.g., including an excitation source 60 and a sensor assembly 70). The field device 60, 70 can generate one or more alternating magnetic fields that the active markers 40 sense, or the field device 60, 70 can sense one or more alternating magnetic fields generated by the active markers 40. In either case, the controller 80 receives location signals from either the field device 60, 70 or the active markers 40 and determines the actual location of the individual markers 40 in a three-dimensional reference frame when the markers are within or on the patient 6. In a particular embodiment of the system illustrated in
In the embodiment shown in
In several embodiments, one or more removable implantable devices 20 are implanted in the patient 6 such that the markers 40 are at least proximate to the resection cavity 7. The removable implantable devices 20 are accordingly associated with the resection cavity such that the implantable device and the markers contained therein move based on the position, rotation, and/or expansion-contraction of the resection cavity 7. In the embodiment shown in
The localization system 10 determines the actual location of the markers 40 in a three-dimensional reference frame when the markers are within or on the patient 6. In a particular embodiment of the system 10 illustrated in
Several embodiments of the implantable device 20 for guided radiation therapy comprises an active marker having a circuit configured to be contained in an external sheath which is implanted in a patient and to transmit a wirelessly transmitted location signal from within the patient in response to a wirelessly transmitted source energy. In an alternative embodiment, the active marker transmits a location signal along a wire. The implantable device can further include a fastening unit for retaining the marker in a fixed position in the external sheath. The marker, for example, can comprise a leadless marker having a circuit with a core and a coil around the core.
Several embodiments of the implantable device 20 enable accurate determination of the size of the resection cavity 7 within the breast of the patient without taking expensive CT images and manually assessing the images. This aspect is very useful because the shape and size of the resection cavity 7 may change over the course of the treatment. This change could cause the external beam radiation to irradiate healthy tissue but miss targeted tissue. By localizing the relative positions of the markers 40, changes in the size and shape of the resection cavity 7 can be determined before, during, and after each treatment session to ensure that the desired dose of radiation is accurately delivered to the correct tissue.
Several embodiments of the implantable device 20 can also track movement of the resection cavity or other treatment target throughout the course of therapy to accurately deliver external beam radiation within the treatment margin. Breast tissue, for example, is soft and pliable such that it may be difficult to hold the treatment target at the isocenter of the external radiation beam. The breast is also likely to move during treatment because of thoracic expansion/contraction caused by respiration. Several embodiments of the implantable device 20 are also useful for detecting movement of the patient or other displacement of the breast in real time during therapy. As a result, the implantable device 20 is expected to provide accurate measurements to confirm the status and the location of the treatment target throughout the course of therapy.
Several embodiments of the implantable device 20 also track the rotational orientation of the resection cavity or other target site relative to the body or the radiation beam throughout the course of treatment. The rotational orientation of the target site may be important in several applications because resection cavities and other targets are generally not spherical such that the rotational orientation affects the profile of the treatment margin relative to the position of the external beam. The markers 40 can be tracked or otherwise located using the localization system 10 to determine rotational orientation of the target relative to the external beam.
Several embodiments of an implantable device 20 for guided radiation therapy comprise an active marker configured to be pre-loaded into a catheter; the catheter is configured to be removeably implanted in the tissue of a patient. The marker transmits a non-ionizing wireless signal in response to a non-ionizing wirelessly transmitted source energy. The implantable device can further include a stability element coupled to the marker and an explant line. The stability element is configured to hold the marker at fixed location within the catheter (e.g., known location) with respect to a target in the tissue. The explant line has a first portion coupled to the marker and/or the stability element and a second portion configured to be at least proximate to the dermis of the patient.
Additional localization and tracking systems are described in U.S. patent and patent application Ser. No. 10/438,550 filed May 14, 2003; U.S. Pat. No. 6,363,940 issued Apr. 2, 2002; U.S. Pat. No. 6,918,919 issued Jul. 19, 2005; U.S. Pat. No. 6,675,810 issued Jan. 13, 2004; Ser. No. 09/877,498 field Jun. 8, 2001; U.S. Pat. No. 7,135,978 issued Nov. 14, 2006; U.S. Pat. No. 6,812,842 issued Nov. 2, 2004; U.S. Pat. No. 6,838,990 issued Jan. 4, 2005; U.S. Pat. No. 6,822,570 issued Nov. 23, 2004; Ser. No. 10/679,801 filed October; and Ser. No. 10/745,097 herein incorporated in their entirety by reference.
A. Basic Devices
1. Removable Implant
According to aspects of the disclosure, a system for fiducials contained in a removable device for use in radiation therapy includes a removable implant device having a cavity configured to receive a fiducial or marker. As shown in
2. Positioning Device
As shown in
3. Fiducials
As shown in
4. External Sheath Fasteners
As shown in
5. Markers
The excitation source 60 (e.g., pulsed magnetic field generator), sensor assembly 70, and controller 80 operate together to localize the markers 40. The excitation source 60 generates an excitation energy to energize at least one of the markers 40a-c in the patient 6. The embodiment of the excitation source 60 shown in
The sensor assembly 70 can include a plurality of coils to sense the location signals L1-3 from the markers 40a-c. The sensor assembly 70 can be a flat panel having a plurality of coils that are at least substantially coplanar relative to each other. In other embodiments, the sensor assembly 70 may be a non-planar array of coils.
The controller 80 includes hardware, software, or other computer-operable media containing instructions that operate the excitation source 60 to multiplex the excitation energy at the different frequencies E1-3. For example, the controller 80 causes the excitation source 60 to generate the excitation energy at the first frequency E1 for a first excitation period, and then the controller 80 causes the excitation source 60 to terminate the excitation energy at the first frequency E1 for a first sensing phase during which the sensor assembly 70 senses the first location signal L1 from the first marker 40a without the presence of the excitation energy at the first frequency E1. The controller 80 then causes the excitation source 60 to (a) generate the second excitation energy at the second frequency E2 for a second excitation period; and (b) terminate the excitation energy at the second frequency E2 for a second sensing phase during which the sensor assembly 70 senses the second location signal L2 from the second marker 40b without the presence of the second excitation energy at the second frequency E2. The controller 80 then repeats this operation with the third excitation energy at the third frequency E3 such that the third marker 40c transmits the third location signal L3 to the sensor assembly 70 during a third sensing phase. As such, the excitation source 60 wirelessly transmits the excitation energy in the form of pulsed magnetic fields at the resonant frequencies of the markers 40a-c during excitation periods, and the markers 40a-c wirelessly transmit the location signals L1-3 to the sensor assembly 70 during sensing phases. It will be appreciated that the excitation and sensing phases can be repeated to permit averaging of the sensed signals to reduce noise.
The computer-operable media in the controller 80, or in a separate signal processor, also includes instructions to determine the absolute positions of each of the markers 40a-c in a three-dimensional reference frame. Based on signals provided by the sensor assembly 70 that correspond to the magnitude of each of the location signals L1-3, the controller 80 and/or a separate signal processor calculates the absolute coordinates of each of the markers 40a-c in the three-dimensional reference frame.
The embodiments of systems and implantable devices for guided radiation therapy described above can be used in methods for treating a patient after a procedure that leaves a resection cavity within the patient. An embodiment of such a method comprises implanting an active marker in tissue of the patient at the resection cavity, wherein the active marker is configured to transmit a non-ionizing wireless signal in response to a non-ionizing wirelessly transmitted source energy, and wherein the marker is coupled to a fastening unit having a distal first portion and a proximal second portion. The method can further include securing the second portion of the fastening unit at least proximate to the dermis of the patient, and localizing the active marker by wirelessly transmitting a non-ionizing source energy to the active marker, transmitting a non-ionizing location signal from the active marker in response to the source energy, and calculating a position of the active marker in an external coordinate system based on the location signal.
B. Real Time Tracking
The localization system 10 and markers 40 enable real time tracking of the target and/or status of the resection cavity or other target relative to an external reference frame outside the patient during treatment planning, setup, irradiation sessions, and other times of the radiation therapy process. In many embodiments, real time tracking means collecting position data of the markers, determining the locations of the markers in an external reference frame (i.e., a reference frame outside the patient), and providing an objective output in the external reference frame responsive to the location of the markers. The objective output is provided at a frequency/periodicity that adequately tracks the target in real time and/or a latency that is at least substantially contemporaneous with collecting the position data (e.g., within a generally concurrent period of time).
For example, several embodiments of real time tracking are defined as determining the locations of the markers and calculating the locations relative to an external reference frame at (a) a sufficiently high frequency/periodicity so that pauses in representations of the target location at a user interface do not interrupt the procedure or are readily discernable by a human, and (b) a sufficiently low latency to be at least substantially contemporaneous with the measurement of the location signals from the markers. Alternatively, real time means that the localization system 10 calculates the absolute position of each individual marker 40 and/or the location of the target at a periodicity of approximately 1 ms to 5 seconds, or in many applications at a periodicity of approximately 10-100 ms, or in some specific applications at a periodicity of approximately 20-50 ms. In applications for user interfaces, for example, the periodicity can be 12.5 ms (i.e., a frequency of 80 Hz), 16.667 ms (60 Hz), 20 ms (50 Hz), and/or 50 ms (20 Hz). Additionally, real time tracking can further mean that the localization system 10 provides the absolute locations of the markers 40 and/or the target to a memory device, user interface, linear accelerator, or other device within a latency of 10 ms to 5 seconds from the time the localization signals were transmitted from the markers 40. In more specific applications, the localization system 10 generally provides the locations of the markers 40, target, or an instrument within a latency of about 20-50 ms. The localization system 10 accordingly provides real time tracking to monitor the position of the markers 40 and/or the target with respect to an external reference frame in a manner that is expected to enhance the efficacy of radiation therapy.
Alternatively, real time tracking can further mean that the localization system 10 provides the absolute locations of the markers 40 and/or the target to a memory device, user interface, or other device within a latency of 10 ms to 5 seconds from the time the localization signals were transmitted from the markers 40. In more specific applications, the location system generally provides the locations of the markers 40 and/or target within a latency of about 20-50 ms. The localization system 10 accordingly provides real time tracking to monitor the position of the markers 40 and/or the target with respect to an external reference frame in a manner that is expected to enhance the efficacy of radiation therapy because higher radiation doses can be applied to the target and collateral effects to healthy tissue can be mitigated.
Alternatively, real-time tracking can further be defined by the tracking error. Measurements of the position of a moving target are subject to motion-induced error, generally referred to as a tracking error. According to specific embodiments, the localization system 10 and at least one marker 40 enable real time tracking of the target or other instrument relative to an external reference frame with a tracking error that is within clinically meaningful limits.
Tracking errors are due to two limitations exhibited by any practical measurement system, specifically (a) latency between the time the target position is sensed and the time the position measurement is made available, and (b) sampling delay due to the periodicity of measurements. For example, if a target is moving at 5 cm/s and a measurement system has a latency of 200 ms, then position measurements will be in error by 1 cm. The error in this example is due to latency alone, independent of any other measurement errors, and is simply due to the fact that the target or instrument has moved between the time its position is sensed and the time the position measurement is made available for use. If the measurement system further has a sampling periodicity of 200 ms (i.e., a sampling frequency of 5 Hz), then the peak tracking error increases to 2 cm, with an average tracking error of 1.5 cm.
For a real time tracking system to be useful in medical applications, it is desirable to keep the tracking error within clinically meaningful limits. For example, in a system for tracking motion of a tumor or an instrument for radiation therapy, it may be desirable to keep the tracking error within 5 mm. Acceptable tracking errors may be smaller when tracking other organs for radiation therapy. In accordance with aspects of the present invention, real time tracking refers to measurement of target position and/or rotation with tracking errors that are within clinically meaningful limits.
B. Basic System Methods
1. Target Identification and Approximate Geometric Center (AGC) Determination
The radiation target, such as a lumpectomy cavity in the breast, may be identified by a traditional imaging technique, for example, by ultrasound. The approximate geometric center (AGC) of the target is roughly determined by the operators, potentially assisted by imaging software tools. One or more reference points to the AGC on the patient's skin can be placed. The insertion trajectories about the AGC for the fiducial sheath are determined by the operators, such that the sheaths when placed will be in general proximity to the AGC. Entrance and exit sites for the sheaths on the skin will be selected. In addition, one could envision a sheath placed into the lumpectomy cavity for purposes of injecting contrast into the cavity or removing fluid from that cavity.
2. Sheath Insertion
An appropriate anesthetic, if needed, is administered to the patient by the surgeon, such as a lidocaine infiltration at the entrance and exit points on the skin and along the projected insertion path. Next, a needle is passed from an entrance point on the skin to its corresponding skin exit point. The sheath (or tail component) is then threaded into the needle. The insertion needle and sheath assembly is then pulled through the tissue. The “missile tip” of the sheath facilitates skin and tissue penetration. Continuous or repeated imaging can be conducted to assess the sheath position relative to the target or GC. The skin fastener can next be applied to provide initial sheath stabilization within the tissue, taking care not to occlude the sheath lumen. The sheath portions protruding from the skin can be trimmed to the desired length. One or more sheaths could be inserted.
3. Filament Afterloading and Positioning
In one embodiment, a filament containing an array of fiducials or specialized markers is then threaded into the sheath. Alternatively, the markers may be pre-loaded or an alternative marker positioning device may be employed to place the markers relative to the removable implant. The filament is positioned such that the fiducials are in proximity to the AGC. This can be assisted by imaging, for example, by ultrasound. For example, an ultrasound image plane through the AGC and the sheath is obtained by the operator. Next, the filament is pulled through the plane until a desired point of that filament is reached as demarked by an ultrasonic marker (which can be the fiducial or a separate marker).
4. Filament Fixation
After the operators have positioned the filament within the removable device, shown in the Figures as a sheath, to their initial satisfaction, an action is applied to the fastener such that the filament is secured within the sheath to prevent subsequent filament movement. Excess filament protruding from the sheath can be trimmed, if desired. A temporary dressing can be placed over the fastener and protruding filament.
5. Radiation Therapy Treatment Planning and Possible Re-Positioning
At the appropriate time following sheath and fiducial, the patient undergoes standard radiation planning simulation. At simulation an image, usually a CT scan, is obtained. A preliminary assessment of the target is obtained. If desired, contrast can be injected into the cavity through one or more of the sheaths to facilitate imaging of the cavity. If after a preliminary assessment of the fiducial relationship to the target AGC indicates a need for better alignment, the fastener can be loosened sufficiently to allow the filament to be repositioned. Once it's determined that fiducial position relative to the AGC is satisfactory, the fastener is closed to secure the filament within the sheath. This realignment process can be made one or more time during the course of radiation therapy should it be necessary.
6. Radiation Therapy Delivery
The prescribed course of radiation therapy is delivered. The fiducials are used to setup and continuously track the patient during treatment. In addition, the fiducials can be used to adapt the radiation to the patient. For example, if the distances between the fiducials changes, they might suggest that there has been some deformation of the target, such as swelling of the lumpectomy cavity. This change may suggest that repeat simulation and re-planning might be indicated. One could envision other adaptations that could be invoked dependent on fiducial tracking. For example, if the patient exhibits excess breathing motion, the radiation could be gated, or a bio-feedback program invoked.
7. Removal
Once the prescribed course of radiation is delivered, the fasteners are released and the sheath containing the fiducial filament is removed. According to alternative embodiments, the removable implant is removed concurrent with the marker removal.
As shown in
As shown in
As shown in
From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but well-known structures and functions have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments of the invention. Where the context permits, singular or plural terms may also include the plural or singular term, respectively. Moreover, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the term “comprising” is used throughout to mean including at least the recited feature(s) such that any greater number of the same feature and/or additional types of features are not precluded. It will also be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the inventions. For example, many of the elements of one of embodiment can be combined with other embodiments in addition to, or in lieu of, the elements of the other embodiments. Accordingly, the invention is not limited except as by the appended claims.
This application claims priority to U.S. Provisional Application Ser. No. 61/146,257, filed on Jan. 21, 2009, entitled “METHOD AND SYSTEM FOR REMOVABLE FIDUCIALS FOR RADIATION THERAPY,” which is hereby incorporated herein in its entirety by reference.
Number | Name | Date | Kind |
---|---|---|---|
3967161 | Lichtblau | Jun 1976 | A |
4023167 | Wahlstrom | May 1977 | A |
4114601 | Abels | Sep 1978 | A |
4123749 | Hartmann et al. | Oct 1978 | A |
4127110 | Bullara | Nov 1978 | A |
4160971 | Jones et al. | Jul 1979 | A |
4222374 | Sampson et al. | Sep 1980 | A |
4260990 | Lichtblau | Apr 1981 | A |
4393872 | Reznik et al. | Jul 1983 | A |
4618822 | Hansen | Oct 1986 | A |
4633250 | Anderson, III et al. | Dec 1986 | A |
4643196 | Tanaka et al. | Feb 1987 | A |
4653496 | Bundy et al. | Mar 1987 | A |
4696287 | Hortmann | Sep 1987 | A |
4795995 | Eccleston et al. | Jan 1989 | A |
4799495 | Hawkins et al. | Jan 1989 | A |
4909789 | Taguchi et al. | Mar 1990 | A |
4936823 | Colvin et al. | Jun 1990 | A |
4945914 | Allen | Aug 1990 | A |
4994079 | Genese et al. | Feb 1991 | A |
5031634 | Simon | Jul 1991 | A |
5062847 | Barnes | Nov 1991 | A |
5095224 | Renger | Mar 1992 | A |
5099845 | Besz et al. | Mar 1992 | A |
5107862 | Fabian | Apr 1992 | A |
5142292 | Chang | Aug 1992 | A |
5170055 | Carroll et al. | Dec 1992 | A |
5325873 | Hirschi et al. | Jul 1994 | A |
5353804 | Kornberg et al. | Oct 1994 | A |
5409004 | Sloan | Apr 1995 | A |
5423334 | Jordan | Jun 1995 | A |
5423744 | Gencheff et al. | Jun 1995 | A |
5425367 | Shapiro et al. | Jun 1995 | A |
5425382 | Golden et al. | Jun 1995 | A |
5431161 | Ryals et al. | Jul 1995 | A |
5446548 | Gerig et al. | Aug 1995 | A |
5509900 | Kirkman | Apr 1996 | A |
5528651 | Leksell et al. | Jun 1996 | A |
5626630 | Markowitz et al. | May 1997 | A |
5638819 | Manwaring | Jun 1997 | A |
5651043 | Tsuyuki et al. | Jul 1997 | A |
5680106 | Schrott et al. | Oct 1997 | A |
5697384 | Miyawaki | Dec 1997 | A |
5707362 | Yoon | Jan 1998 | A |
5707390 | Bonutti | Jan 1998 | A |
5711299 | Manwaring | Jan 1998 | A |
5727552 | Ryan | Mar 1998 | A |
5735795 | Young et al. | Apr 1998 | A |
5748767 | Raab | May 1998 | A |
5754623 | Seki | May 1998 | A |
5757881 | Hughes | May 1998 | A |
5764052 | Renger | Jun 1998 | A |
5769861 | Vilsmeier | Jun 1998 | A |
5810851 | Yoon | Sep 1998 | A |
5815076 | Herring | Sep 1998 | A |
5840148 | Campbell et al. | Nov 1998 | A |
5868673 | Vesely | Feb 1999 | A |
5879297 | Haynor et al. | Mar 1999 | A |
5902310 | Foerster et al. | May 1999 | A |
5910144 | Hayashi | Jun 1999 | A |
5911717 | Jacobsen et al. | Jun 1999 | A |
5928137 | Green | Jul 1999 | A |
5941890 | Voegele et al. | Aug 1999 | A |
5951481 | Evans | Sep 1999 | A |
5951514 | Sahota | Sep 1999 | A |
5957934 | Rapoport | Sep 1999 | A |
5989265 | Bouquet De La Joliniere | Nov 1999 | A |
6026818 | Blair | Feb 2000 | A |
6059734 | Yoon | May 2000 | A |
6061644 | Leis | May 2000 | A |
6066158 | Engelson et al. | May 2000 | A |
6067465 | Foo et al. | May 2000 | A |
6076008 | Bucholz | Jun 2000 | A |
6081238 | Alicot | Jun 2000 | A |
6082366 | Andra et al. | Jul 2000 | A |
6144875 | Schweikard et al. | Nov 2000 | A |
6161009 | Skurdal et al. | Dec 2000 | A |
6198963 | Haim et al. | Mar 2001 | B1 |
6220248 | Voegele et al. | Apr 2001 | B1 |
6222544 | Tarr et al. | Apr 2001 | B1 |
6228055 | Foerster et al. | May 2001 | B1 |
6234177 | Barsch | May 2001 | B1 |
6246900 | Cosman et al. | Jun 2001 | B1 |
6272371 | Shlomo | Aug 2001 | B1 |
6307473 | Zampini et al. | Oct 2001 | B1 |
6325758 | Carol et al. | Dec 2001 | B1 |
6336904 | Nikolchev | Jan 2002 | B1 |
6353655 | Siochi | Mar 2002 | B1 |
6356782 | Sirimanne et al. | Mar 2002 | B1 |
6359959 | Butler et al. | Mar 2002 | B1 |
6360116 | Jackson, Jr. et al. | Mar 2002 | B1 |
6363940 | Krag | Apr 2002 | B1 |
6371379 | Dames et al. | Apr 2002 | B1 |
6371904 | Sirimanne et al. | Apr 2002 | B1 |
6377162 | Delestienne et al. | Apr 2002 | B1 |
6381485 | Hunter et al. | Apr 2002 | B1 |
6385286 | Fitchard et al. | May 2002 | B1 |
6385288 | Kanematsu | May 2002 | B1 |
6393096 | Carol et al. | May 2002 | B1 |
6405072 | Cosman | Jun 2002 | B1 |
6416520 | Kynast et al. | Jul 2002 | B1 |
6425903 | Voegele | Jul 2002 | B1 |
6447448 | Ishikawa et al. | Sep 2002 | B1 |
6498944 | Ben-Haim et al. | Dec 2002 | B1 |
6501981 | Schweikard et al. | Dec 2002 | B1 |
6535756 | Simon et al. | Mar 2003 | B1 |
6574492 | Ben-Haim et al. | Jun 2003 | B1 |
6638231 | Govari et al. | Oct 2003 | B2 |
6654629 | Montegrande | Nov 2003 | B2 |
6675810 | Krag | Jan 2004 | B2 |
6698433 | Krag | Mar 2004 | B2 |
6725083 | Burbank et al. | Apr 2004 | B1 |
6766186 | Hoyns et al. | Jul 2004 | B1 |
6812842 | Dimmer | Nov 2004 | B2 |
6822570 | Dimmer et al. | Nov 2004 | B2 |
6838990 | Dimmer | Jan 2005 | B2 |
6918919 | Krag | Jul 2005 | B2 |
6934356 | Satheesan et al. | Aug 2005 | B1 |
6937696 | Mostafavi | Aug 2005 | B1 |
6977504 | Wright et al. | Dec 2005 | B2 |
6993375 | Burbank et al. | Jan 2006 | B2 |
6999555 | Morf | Feb 2006 | B2 |
7026927 | Wright et al. | Apr 2006 | B2 |
7027707 | Imaki | Apr 2006 | B2 |
7044957 | Foerster et al. | May 2006 | B2 |
7047063 | Burbank et al. | May 2006 | B2 |
7135978 | Gisselberg et al. | Nov 2006 | B2 |
7142905 | Slayton et al. | Nov 2006 | B2 |
7174201 | Govari et al. | Feb 2007 | B2 |
7176798 | Dimmer et al. | Feb 2007 | B2 |
7206626 | Quaid, III | Apr 2007 | B2 |
7206627 | Abovitz et al. | Apr 2007 | B2 |
7213009 | Pestotnik et al. | May 2007 | B2 |
7221733 | Takai et al. | May 2007 | B1 |
7229417 | Foerster et al. | Jun 2007 | B2 |
7280863 | Shacher | Oct 2007 | B2 |
7289839 | Dimmer et al. | Oct 2007 | B2 |
7318805 | Schweikard et al. | Jan 2008 | B2 |
7397364 | Govari | Jul 2008 | B2 |
7447643 | Olson et al. | Nov 2008 | B1 |
7534252 | Sepetka | May 2009 | B2 |
7535363 | Gisselberg et al. | May 2009 | B2 |
7558616 | Govari et al. | Jul 2009 | B2 |
7565191 | Burbank et al. | Jul 2009 | B2 |
7590441 | Govari | Sep 2009 | B2 |
7599730 | Hunter et al. | Oct 2009 | B2 |
7606405 | Sawyer et al. | Oct 2009 | B2 |
7625397 | Foerster et al. | Dec 2009 | B2 |
7657301 | Mate et al. | Feb 2010 | B2 |
7657302 | Mate et al. | Feb 2010 | B2 |
7657303 | Mate et al. | Feb 2010 | B2 |
7668582 | Sirimanne et al. | Feb 2010 | B2 |
7696876 | Dimmer | Apr 2010 | B2 |
7729742 | Govari | Jun 2010 | B2 |
7778687 | Dimmer et al. | Aug 2010 | B2 |
7780973 | Freeman et al. | Aug 2010 | B2 |
7912529 | Herron et al. | Mar 2011 | B2 |
8046052 | Verard et al. | Oct 2011 | B2 |
8060185 | Hunter et al. | Nov 2011 | B2 |
8196589 | Gisselberg | Jun 2012 | B2 |
8239002 | Neustadter et al. | Aug 2012 | B2 |
8239005 | Wright et al. | Aug 2012 | B2 |
8277391 | Foerster | Oct 2012 | B2 |
8306602 | Sirimanne | Nov 2012 | B2 |
8320993 | Sirimanne | Nov 2012 | B2 |
8320994 | Sirimanne | Nov 2012 | B2 |
8401616 | Verard | Mar 2013 | B2 |
8452375 | Krag | May 2013 | B2 |
8467853 | Hunter | Jun 2013 | B2 |
8549960 | Hoff | Oct 2013 | B2 |
20020065461 | Cosman | May 2002 | A1 |
20020083951 | Stegmaier et al. | Jul 2002 | A1 |
20020107437 | Sirimanne et al. | Aug 2002 | A1 |
20020165443 | Mori | Nov 2002 | A1 |
20020193685 | Mate et al. | Dec 2002 | A1 |
20030023161 | Govari et al. | Jan 2003 | A1 |
20030181794 | Rini | Sep 2003 | A1 |
20030192557 | Krag et al. | Oct 2003 | A1 |
20030206610 | Collins | Nov 2003 | A1 |
20030206614 | Kendrick et al. | Nov 2003 | A1 |
20040024304 | Foerster et al. | Feb 2004 | A1 |
20040068182 | Misra | Apr 2004 | A1 |
20050059888 | Sirimanne et al. | Mar 2005 | A1 |
20050080338 | Sirimanne et al. | Apr 2005 | A1 |
20050080339 | Sirimanne et al. | Apr 2005 | A1 |
20050085895 | Brown et al. | Apr 2005 | A1 |
20050101824 | Stubbs | May 2005 | A1 |
20050113855 | Kennedy et al. | May 2005 | A1 |
20050165305 | Foerster et al. | Jul 2005 | A1 |
20050182319 | Glossop | Aug 2005 | A1 |
20050273002 | Goosen et al. | Dec 2005 | A1 |
20060074443 | Foerster et al. | Apr 2006 | A1 |
20060093089 | Vertatschitsch et al. | May 2006 | A1 |
20060094923 | Mate | May 2006 | A1 |
20080021308 | Dimmer et al. | Jan 2008 | A1 |
20080287781 | Revie | Nov 2008 | A1 |
20090259284 | Yamasaki et al. | Oct 2009 | A1 |
20090278689 | Gisselberg et al. | Nov 2009 | A1 |
20090299174 | Wright et al. | Dec 2009 | A1 |
Number | Date | Country |
---|---|---|
9603925 | Feb 1996 | WO |
0016686 | Mar 2000 | WO |
0239917 | May 2002 | WO |
204061460 | Jul 2004 | WO |
WO 2005067792 | Jul 2005 | WO |
WO 2006020377 | Feb 2006 | WO |
Number | Date | Country | |
---|---|---|---|
61146257 | Jan 2009 | US |